— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.
— Total revenues edged up to $6.01 million from $5.9 million in 2018
— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019
— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline
— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization
— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments
— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020
Most Popular
American Express (AXP) Q2 2025 Earnings: Key financials and quarterly highlights
American Express Company (NYSE: AXP) reported its second quarter 2025 earnings results today. Consolidated total revenues, net of interest expense, were $17.9 billion, up 9% year-over-year, driven by increased Card
Netflix Q2 earnings jump on strong revenue growth; results beat estimates
Video streaming giant Netflix, Inc. (NASDAQ: NFLX) reported a sharp increase in revenue and profit for the second quarter of fiscal 2025. The numbers also beat analysts' estimates. The company's
Tesla Q2 Earnings Preview: Can energy gains offset EV demand Slump?
For Tesla Inc. (NASDAQ: TSLA), the new fiscal year has been quite challenging, with first-quarter sales falling to a three-year low amid production issues related to Model Y and increasing
